

## Saskatchewan Immunization Manual Amendments February 2023

**Instructions:** Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

### Chapter 5 Immunization Schedules

- Section 3.7 Tetanus Prophylaxis in Wound Management
  - Footnote #5 revised, now states: Tlg should be given as soon as possible, ideally within 24 hours after a tetanus prone wound has occurred. In rare circumstances where Tlg is not available or there is a delay in the client reporting or presenting for follow up, it can be given up to 21 days after sustaining injury, based on the incubation period of 3-21 days. If more than 21 days or if a tetanus-containing vaccine was given prior to Tlg, consult with MOH/MOH designate.

### Chapter 7 Immunization of Special Populations

- Appendix 7.8: Publicly Funded Immigrant and Refugee Immunization and Serology Recommendations
  - HB serology no longer required for those 18+ prior to immunization, so original footnote #1 deleted.
  - HC map link updated.

### Chapter 8 Administration of Biological Products

- Certolizumab pegol (CIMZIA) added to list in Appendix 8.2 Monoclonal Antibody Medications

### Chapter 10 Biological Products

- TOC page 1 revised:
  - MODERNA Spikevax® 0/0 Original/Omicron BA.1 **Bivalent** formulation (Blue cap/green label) now licensed for 6+ years.
- COVID-19 Booster Dose Parameters and Recommendations
  - Fourth bullet revised and new row added, as Modern Spikevax BA.1 Bivalent authorized as booster for 6-11 years (25 mcg) and 12-17 (50 mcg).
- COVID-19 Vaccine Q &A for Immunizers
  - Previous intervals for booster doses revised to state 6 months.
  - #5 – Age 18 changed to 12 years for myocarditis risk.
  - #6 – Previous scenario of off-label Modern bivalent for 12-17 years removed.
  - **New #12: Is there a preferred vaccine brand to be offered to immunocompromised individuals?**  
Response: Yes, Moderna is the preferred vaccine brand for those who are moderately to severely immunocompromised.
- Modern Spikevax Bivalent BA.1 6+ years
  - Age indication revised to 6 years.
  - Dosages revised for 6-11 years (25 mcg) and 12+ years (50 mcg).
  - Product monograph date updated.
- Moderna Spikevax® Monovalent 6+ years (Red cap/light blue label) page 6 of 6
  - Product monograph date updated
- Novavax Nuvaxovid
  - Product monograph updated to 2023-02-09.
  - **New bullet** added under Contraindications: The product monograph states, “A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of NUVAXOVID”.
  - **Revised bullets** added to Precautions:

## Saskatchewan Immunization Manual Amendments February 2023

- Myocarditis and pericarditis have been reported following NUVAXOVID administration.
  - Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis and pericarditis in general.
  - Available data cannot determine a causal association with NUVAXOVID.
  - Vaccinated individuals (including parents or caregivers) should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis such as (acute and persisting) chest pain, shortness of breath, or palpitations following vaccination.
- **New bullet** added under Pregnancy
  - There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to NUVAXOVID during pregnancy. Women who are vaccinated with NUVAXOVID during pregnancy are encouraged to enroll in the registry by visiting <https://c-viper.pregistry.com/>.
- **New bullet** added under Possible Reactions section: Hypoesthesia and paresthesia have been reported as post-market adverse reactions.
- Pfizer Comirnaty BA. 4/5 12+ and 5-11 years bivalent vaccines product monograph date updated to 2023-02-09, as shelf extended from 12-18 months as noted in storage and handling sections.
- Publicly Funded Hepatitis A (HA) Vaccine Indications
  - 6 months added to select publicly funded indications.
  - **New footnote #3** added: CIG Hepatitis A chapter <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html>.
  - Pharmacists added to footnote #2.
- AVAXIM HA vaccine
  - **New note** added to child dose/series:
    - In SK, AVAXIM Pediatric may be provided off-label to those 6-11 months.
- Havrix HA vaccine
  - **New note** added to Adult and child dose/series:
    - In SK, AVAXIM Pediatric may be provided off-label to those 6-11 months.
    - In SK, HAVRIX 1440 may be provided off-label to those 18 years old if another adult HA vaccine brand is unavailable.
- VAQTA HA vaccine
  - **New note** added to child dose/series:
    - In SK, VAQTA Pediatric may be provided off-label to those 6-11 months.
- Publicly Funded Hepatitis B (HB) Vaccine Indications
  - Pharmacists added to footnote #8.
- SHINGRIX product monograph date updated.
- MMRV (ProQuad and Priorix-Tetra)
  - Indication revised to: Healthy children 1 year up to and including 12 years of age who require protection against MMR and varicella diseases.
  - ProQuad product monograph date and link updated.
- NIMENRIX
  - Product monograph date and link updated.
  - Infant schedule updated to align with product monograph.

### Chapter 14 – Appendices

- APPENDIX 14.2: Former REGIONAL HEALTH AUTHORITIES AND FIRST NATIONS JURISDICTIONS
  - Indigenous Services Canada and former Five Hills Health Region information updated.